PharmaLogic Holdings Corp. will acquire a majority stake in Agilera Pharma AS from the Institute for Energy Technology (IFE) in Norway, marking a significant step forward in the company's strategy to create the first fully-integrated, global CDMO specializing in radiopharmaceutical therapies.
Agilera has been a trusted partner for major pharmaceutical companies for more than a decade, manufacturing commercial radiopharmaceutical therapies across the United States, Europe, and Asia. With more than 600,000 commercial therapeutic doses delivered to more than 40 countries, Agilera stands as a leader in the radiopharmaceutical CDMO space, further advancing PharmaLogic's commitment to innovation and excellence in the industry.
"PharmaLogic's acquisition of Agilera, one of only two CDMOs worldwide currently manufacturing radiopharmaceutical therapeutics, accelerates the expansion of our capabilities in this high-growth field," said Etienne Montagut, President of PharmaLogic. "By combining our expertise with Agilera's industry-leading scale and quality systems, we will be uniquely positioned to offer an end-to-end solution for manufacturing therapeutics at scale and ultimately improve global patient access to these essential treatments. We're thrilled to welcome Agilera's very talented team to PharmaLogic and to take the lead in expanding our presence in Europe."
Under the terms of the agreement, Agilera will complement PharmaLogic's existing manufacturing platform for therapeutics, enhancing the company's ability to deliver world-class radiopharmaceutical solutions. PharmaLogic is committed to investing in the expansion of Agilera's CDMO capabilities, strengthening its infrastructure, and scaling its manufacturing footprint to meet rising global demand for radiopharmaceutical therapeutics. This acquisition establishes PharmaLogic as the only CDMO with a global presence actively producing and distributing one of the main commercially-approved radiopharmaceutical therapies for major pharmaceutical companies.
From Nils Morten Huseby, CEO of IFE: "For IFE, the sale of a majority stake in Agilera marks a significant achievement as the largest commercialization effort carried out from the Institute to date. As a leading Research Institute, IFE is committed to innovation and job creation and has played a key role in the development and manufacturing of radiopharmaceutical therapeutics through Agilera. The entry of PharmaLogic as a new majority shareholder in Agilera will enable rapid scale-up, growth and development of Agilera's operations to meet the increased demand for radiopharmaceutical therapeutics globally."
"At Agilera, we highly welcome PharmaLogic as a majority shareholder in the company. Agilera's most important asset is the experience and expertise of our employees, as the company with the longest experience in large-scale production of radiotherapeutics globally. With PharmaLogic as a new owner beside IFE, this will enable further investments in the business to ensure that we have the right, available capacity to take on new customer projects and thus achieve faster adaptation to the promising market opportunities," said Erik Flatmark, CEO of Agilera. "An important step will be to strengthen European and transatlantic distribution of the products from both companies. We feel confident that we together will provide great opportunities for European, U.S., and global customers, with increased manufacturing capacity and capability in the market."